{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=2", "query": { "intervention": "Combination 600", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+600&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-14T01:05:23.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03639935", "title": "Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-28", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639935" }, { "nct_id": "NCT00092222", "title": "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorder", "HHV-8", "Malignancy", "HIV" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim (G-CSF)", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Observation Only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2004-10-28", "completion_date": "2026-10-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00092222" }, { "nct_id": "NCT02327169", "title": "A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "MLN2480", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2015-01-14", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02327169" }, { "nct_id": "NCT03078751", "title": "Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Adjuvant endocrine therapy", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-06-20", "completion_date": "2020-03-09", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 33, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078751" }, { "nct_id": "NCT05174039", "title": "An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Batten Disease" ], "interventions": [ { "name": "Miglustat 100 milligrams (mg) Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beyond Batten Disease Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 6, "start_date": "2022-03-10", "completion_date": "2024-05-30", "has_results": true, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05174039" }, { "nct_id": "NCT03449901", "title": "ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "pegylated arginine deiminase", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Tumor biopsy", "type": "PROCEDURE" }, { "name": "Research blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 98, "start_date": "2018-05-09", "completion_date": "2022-07-08", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 4, "location_summary": "Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449901" }, { "nct_id": "NCT01641809", "title": "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1265744 10 mg", "type": "DRUG" }, { "name": "GSK1265744 30 mg", "type": "DRUG" }, { "name": "GSK1265744 60 mg", "type": "DRUG" }, { "name": "Efavirenz 600 mg", "type": "DRUG" }, { "name": "Rilpivirine 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-08-06", "completion_date": "2019-01-15", "has_results": true, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641809" }, { "nct_id": "NCT02720094", "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Oral Tablet", "type": "DRUG" }, { "name": "TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for cabotegravir oral tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Placebo for CAB LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4570, "start_date": "2016-12-19", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02720094" }, { "nct_id": "NCT00216112", "title": "Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniela Matei, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2003-12", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2016-02-19", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 9, "location_summary": "Galesburg, Illinois • Elkhart, Indiana • Evansville, Indiana + 6 more", "locations": [ { "city": "Galesburg", "state": "Illinois" }, { "city": "Elkhart", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00216112" }, { "nct_id": "NCT02532283", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza A Virus" ], "interventions": [ { "name": "JNJ-63623872", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 102, "start_date": "2015-12-11", "completion_date": "2017-03-15", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-09-14T01:05:23.887Z", "location_count": 14, "location_summary": "Fresno, California • Long Beach, California • Stanford, California + 11 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlantis", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532283" } ] }